Yuhang Xiao

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Combretastatin A-4 (CA4) is the lead compound of a relatively new class of vascular disrupting agents that target existing tumor blood vessels. Recent studies showed the CA4 might inhibit angiogenesis. However, the underlying molecular mechanisms by which CA4 exerts its anti-angiogenic effects are not fully understood. In this study, we revealed that CA4(More)
  • 1